LeMaitre (NASDAQ:LMAT) Reports Sales Below Analyst Estimates In Q3 Earnings

Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of $62.8 million underwhelmed, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 31.5% above analysts’ consensus estimates. Is now the time to buy LeMaitre? Find out in our full research report. LeMaitre (LMAT) Q3 CY2025 Highlights: Revenue: $61.05 million vs analyst estimate ...